Skip to main content

Advertisement

SpringerLink
Log in

The intriguing connections of leptin to hyperparathyroidism

  • Review
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

Leptin has been implicated in bone metabolism, but the association with parathyroid gland function has not been fully clarified. This review aimed to summarize evidence of the association between leptin and hyperparathyroidism, both primary and secondary, elucidating the potential pathophysiologic and therapeutic consequences between leptin and parathyroid hormone, hopefully prompting the design of new studies.

Results

Experimental studies indicate a positive loop between leptin and parathyroid hormone in primary hyperparathyroidism. Dissimilar, parathyroid hormone seems to inhibit leptin expression in severe secondary hyperparathyroidism. Data from clinical studies indicate higher leptin levels in patients with primary hyperparathyroidism than controls, but no association between parathyroid hormone and leptin levels, as well as a minimal or neutral effect of parathyroidectomy on leptin levels in patients with primary hyperparathyroidism. Clinical data on secondary hyperparathyroidism, mainly derived from patients with chronic kidney disease, indicate a potential inverse association between leptin and parathyroid hormone in some, but not all studies. This relationship may be affected by the diversity of morbidity among these patients.

Conclusions

Data from experimental studies suggest a different association between leptin and parathyroid hormone in primary and secondary hyperparathyroidism. Data from clinical studies are conflicting and potentially affected by confounders. More focused, well-designed studies are warranted to elucidate a potential association between leptin and parathyroid hormone, which may have specific clinical implications, i.e., targeting obesity and hyperleptinemia in patients with hyperparathyroidism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. S.A. Polyzos, P. Makras, Z. Efstathiadou, A.D. Anastasilakis, Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Exp. Opin. Investig. Drugs 24, 145–157 (2015)

    Article  CAS  Google Scholar 

  2. W.D. Fraser, Hyperparathyroidism. Lancet 374, 145–158 (2009)

    Article  CAS  PubMed  Google Scholar 

  3. A.A. Khan, D.A. Hanley, R. Rizzoli, J. Bollerslev, J.E. Young, L. Rejnmark, R. Thakker, P. D’Amour, T. Paul, S. Van Uum, M.Z. Shrayyef, D. Goltzman, S. Kaiser, N.E. Cusano, R. Bouillon, L. Mosekilde, A.W. Kung, S.D. Rao, S.K. Bhadada, B.L. Clarke, J. Liu, Q. Duh, E.M. Lewiecki, F. Bandeira, R. Eastell, C. Marcocci, S.J. Silverberg, R. Udelsman, K.S. Davison, J.T. Potts Jr., M.L. Brandi, J.P. Bilezikian, Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos. Int. 28, 1–19 (2017)

    Article  CAS  PubMed  Google Scholar 

  4. M.J. Bolland, A.B. Grey, G.D. Gamble, I.R. Reid, Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 1525–1530 (2005)

    Article  CAS  PubMed  Google Scholar 

  5. M.A. Adam, B.R. Untch, M.E. Danko, S. Stinnett, D. Dixit, J. Koh, J.R. Marks, J.A. Olson Jr., Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 95, 4917–4924 (2010)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. S.A. Polyzos, C.S. Mantzoros, Leptin in health and disease: facts and expectations at its twentieth anniversary. Metabolism 64, 5–12 (2015)

    Article  CAS  PubMed  Google Scholar 

  7. S.P. Cheng, G.M. Doherty, Y.C. Chang, C.L. Liu, Leptin: the link between overweight and primary hyperparathyroidism? Med. Hypotheses 76, 94–96 (2011)

    Article  CAS  PubMed  Google Scholar 

  8. B.E. Wolfe, D.C. Jimerson, C. Orlova, C.S. Mantzoros, Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin. Endocrinol. 61, 332–338 (2004)

    Article  CAS  Google Scholar 

  9. M. Dalamaga, S.H. Chou, K. Shields, P. Papageorgiou, S.A. Polyzos, C.S. Mantzoros, Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell. Metab. 18, 29–42 (2013)

    Article  CAS  PubMed  Google Scholar 

  10. S.A. Polyzos, J. Kountouras, C. Zavos, G. Deretzi, The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J. Clin. Gastroenterol. 45, 50–54 (2011)

    Article  CAS  PubMed  Google Scholar 

  11. S.A. Polyzos, J. Kountouras, C.S. Mantzoros, Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism 64, 60–78 (2015)

    Article  CAS  PubMed  Google Scholar 

  12. M.A. Tsoukas, O.M. Farr, C.S. Mantzoros, Leptin in congenital and HIV-associated lipodystrophy. Metabolism 64, 47–59 (2015)

    Article  CAS  PubMed  Google Scholar 

  13. M. Karakose, M. Caliskan, M.S. Arslan, T. Demirci, S. Karakose, E. Cakal, The impact of parathyroidectomy on serum ADAMTS1, ADAMTS4 levels, insulin resistance, and subclinical cardiovascular disease in primary hyperparathyroidism. Endocrine 55, 283–288 (2017)

    Article  CAS  PubMed  Google Scholar 

  14. D. Sit, A.K. Kadiroglu, M.E. Yilmaz, I.H. Kara, B. Isikoglu, The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients. Ren. Fail. 27, 403–407 (2005)

    Article  CAS  PubMed  Google Scholar 

  15. H.S. Moon, M. Dalamaga, S.Y. Kim, S.A. Polyzos, O.P. Hamnvik, F. Magkos, J. Paruthi, C.S. Mantzoros, Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr. Rev. 34, 377–412 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. J. Upadhyay, O.M. Farr, C.S. Mantzoros, The role of leptin in regulating bone metabolism. Metabolism 64, 105–113 (2015)

    Article  CAS  PubMed  Google Scholar 

  17. X.X. Chen, T. Yang, Roles of leptin in bone metabolism and bone diseases. J. Bone. Miner. Metab. 33, 474–485 (2015)

    Article  CAS  PubMed  Google Scholar 

  18. A. Matsunuma, T. Kawane, T. Maeda, S. Hamada, N. Horiuchi, Leptin corrects increased gene expression of renal 25-hydroxyvitamin D3-1 alpha-hydroxylase and -24-hydroxylase in leptin-deficient, ob/ob mice. Endocrinology 145, 1367–1375 (2004)

    Article  CAS  PubMed  Google Scholar 

  19. K. Tsuji, T. Maeda, T. Kawane, A. Matsunuma, N. Horiuchi, Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J. Bone. Miner. Res. 25, 1711–1723 (2010)

    Article  CAS  PubMed  Google Scholar 

  20. I. Lopez, C. Pineda, A.I. Raya, M.E. Rodriguez-Ortiz, J.M. Diaz-Tocados, R. Rios, J.M. Rodriguez, E. Aguilera-Tejero, Y. Almaden, Leptin directly stimulates parathyroid hormone secretion. Endocrine 56, 675–678 (2016)

    Article  PubMed  Google Scholar 

  21. J. George, The parathyroid leptin axis. Endocrine 56, 458–459 (2017)

    Article  CAS  PubMed  Google Scholar 

  22. D. Hoang, N. Broer, J.A. Sosa, N. Abitbol, X. Yao, F. Li, F. Rivera-Molina, D.K. Toomre, S.A. Roman, G. Sue, S. Kim, A.Y. Li, G.G. Callender, C. Simpson, D. Narayan, Leptin is produced by parathyroid glands and stimulates parathyroid hormone secretion. Ann. Surg. (2016). doi:10.1097/SLA.0000000000002004

  23. Y. Jiang, J. Zhang, Y. Yuan, X. Zha, C. Xing, C. Shen, Z. Shen, C. Qin, M. Zeng, G. Yang, H. Mao, B. Zhang, X. Yu, B. Sun, C. Ouyang, X. Xu, Y. Ge, J. Wang, L. Zhang, C. Cheng, C. Yin, J. Zhang, H. Chen, H. Ma, N. Wang, Association of increased serum leptin with ameliorated anemia and malnutrition in stage 5 chronic kidney disease patients after parathyroidectomy. Sci. Rep. 6, 27918 (2016)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. E. Delfini, L. Petramala, C. Caliumi, D. Cotesta, G. De Toma, G. Cavallaro, G. Panzironi, D. Diacinti, S. Minisola, D.E. E, G.F. Mazzuoli, C. Letizia, Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism 56, 30–36 (2007)

    Article  CAS  PubMed  Google Scholar 

  25. S.K. Bhadada, A. Bhansali, V.N. Shah, D.S. Rao, Changes in serum leptin and adiponectin concentrations and insulin resistance after curative parathyroidectomy in moderate to severe primary hyperparathyroidism. Singapore Med. J. 52, 890–893 (2011)

    CAS  PubMed  Google Scholar 

  26. D.A. de Luis, G.D. Soto, R. Conde, O. Izaola, B. de la Fuente, Relation of leptin and adiponectin with cardiovascular risk factors, intact parathormone, and vitamin D levels in patients with primary hyperparathyroidism. J. Clin. Lab. Anal. 26, 398–402 (2012)

    Article  Google Scholar 

  27. D. Hoang, N. Broer, S.A. Roman, X. Yao, N. Abitbol, F. Li, J.A. Sosa, G.R. Sue, A.T. DeWan, M.L. Wong, J. Licinio, C. Simpson, A.Y. Li, N. Pizzoferrato, D. Narayan, Leptin signaling and hyperparathyroidism: clinical and genetic associations. J. Am. Coll. Surg. 218, 1239–1250 (2014). e1234

    Article  PubMed  Google Scholar 

  28. J. Bollerslev, T. Rosen, C.L. Mollerup, J. Nordenstrom, M. Baranowski, C. Franco, Y. Pernow, G.A. Isaksen, K. Godang, T. Ueland, S. Jansson, S.S. Group, Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94, 2255–2261 (2009)

    Article  CAS  Google Scholar 

  29. F. Kokot, J. Chudek, H. Karkoszka, M. Adamczak, A. Wiecek, D. Klimek, Does PTH influence leptin concentration in haemodialysed uraemic patients? Nephron 82, 372–373 (1999)

    Article  CAS  PubMed  Google Scholar 

  30. R. Pecoits-Filho, L. Nordfors, O. Heimburger, B. Lindholm, B. Anderstam, A. Marchlewska, P. Stenvinkel, Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. Eur. J. Clin. Invest. 32, 811–817 (2002)

    Article  CAS  PubMed  Google Scholar 

  31. G. Coen, P. Ballanti, M.S. Fischer, A. Balducci, S. Calabria, L. Colamarco, G.Di Zazzo, F. Lifrieri, M. Manni, D. Sardella, I. Nofroni, E. Bonucci, Serum leptin in dialysis renal osteodystrophy. Am. J. Kidney Dis. 42, 1036–1042 (2003)

    Article  CAS  PubMed  Google Scholar 

  32. J. Axelsson, A.R. Qureshi, O. Heimburger, B. Lindholm, P. Stenvinkel, P. Barany, Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am. J. Kidney Dis. 46, 628–634 (2005)

    Article  CAS  PubMed  Google Scholar 

  33. C.P. Kovesdy, M.Z. Molnar, M.E. Czira, A. Rudas, A. Ujszaszi, L. Rosivall, M. Szathmari, A. Covic, A. Keszei, G. Beko, P. Lakatos, J. Kosa, I. Mucsi, Associations between serum leptin level and bone turnover in kidney transplant recipients. Clin. J. Am. Soc. Nephrol. 5, 2297–2304 (2010)

    Article  PubMed Central  Google Scholar 

  34. T.A. Ghonemy, E.M. Salim, M. Atia, A. Fekry, K. Shawky, Serum leptin and bone mineral density in hemodialysis patients with or without liver diseases. Arab J. Nephrol. Transplant. 4, 131–136 (2011)

    Article  PubMed  Google Scholar 

  35. O. Ulutas, H. Taskapan, M.C. Taskapan, I. Temel, Vitamin D deficiency, insulin resistance, serum adipokine, and leptin levels in peritoneal dialysis patients. Int. Urol. Nephrol. 45, 879–884 (2013)

    Article  CAS  PubMed  Google Scholar 

  36. Y. Jiang, Z. Shen, J. Zhang, C. Xing, X. Zha, C. Shen, M. Zeng, G. Yang, H. Mao, B. Zhang, X. Yu, B. Sun, C. Ouyang, Y. Ge, L. Zhang, C. Cheng, J. Zhang, C. Yin, H. Chen, N. Wang, Parathyroidectomy increases heart rate variability and leptin levels in patients with stage 5 chronic kidney disease. Am. J. Nephrol. 44, 245–254 (2016)

    Article  CAS  PubMed  Google Scholar 

  37. A.C. Baxmann, V.B. Menon, J.O. Medina-Pestana, A.B. Carvalho, I.P. Heilberg, Overweight and body fat are predictors of hypovitaminosis D in renal transplant patients. Clin. Kidney J. 8, 49–53 (2015)

    Article  PubMed  Google Scholar 

  38. J.P. Tsai, M.C. Lee, Y.C. Chen, G.J. Ho, M.H. Shih, B.G. Hsu, Hyperleptinemia is a risk factor for the development of central arterial stiffness in kidney transplant patients. Transplant. Proc. 47, 1825–1830 (2015)

    Article  CAS  PubMed  Google Scholar 

  39. T. Hryszko, S. Brzosko, A. Rydzewska-Rosolowska, E. Koc-Zorawska, B. Naumnik, M. Mysliwiec, Effect of secondary hyperparathyroidism treatment with cinacalcet on selected adipokines and markers of endothelial injury in hemodialysis patients: a preliminary report. Pol. Arch. Med. Wewn. 122, 148–153 (2012)

    CAS  Google Scholar 

  40. A. Polymeris, K. Doumouchtsis, E. Grapsa, Bone mineral density and bone metabolism in hemodialysis patients. Correlation with PTH, 25OHD3 and leptin. Nefrologia 32, 73–78 (2012)

    CAS  PubMed  Google Scholar 

  41. F. Ahmadi, S. Salari, S. Maziar, F. Esfahanian, Z. Khazaeipour, N. Ranjbarnovin, Relationship between serum leptin levels and bone mineral density and bone metabolic markers in patients on hemodialysis. Saudi J. Kidney. Dis. Transpl. 24, 41–47 (2013)

    Article  PubMed  Google Scholar 

  42. M. Ghorban-Sabbagh, F. Nazemian, M. Naghibi, M.T. Shakeri, S. Ahmadi-Simab, R. Javidi-Dasht-Bayaz, Correlation between serum leptin and bone mineral density in hemodialysis patients. J. Renal. Inj. Prev. 5, 112–117 (2016)

    Article  PubMed  PubMed Central  Google Scholar 

  43. C. Zoccali, V. Panuccio, G. Tripepi, S. Cutrupi, P. Pizzini, F. Mallamaci, Leptin and biochemical markers of bone turnover in dialysis patients. J. Nephrol. 17, 253–260 (2004)

    CAS  Google Scholar 

  44. S.A. Polyzos, C.S. Mantzoros, Nonalcoholic fatty future disease. Metabolism 65, 1007–1016 (2016)

    Article  CAS  PubMed  Google Scholar 

  45. S.A. Polyzos, K.N. Aronis, J. Kountouras, D.D. Raptis, M.F. Vasiloglou, C.S. Mantzoros, Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 59, 30–43 (2016)

    Article  CAS  PubMed  Google Scholar 

  46. K. Liu, P. Liu, R. Liu, X. Wu, M. Cai, Relationship between serum leptin levels and bone mineral density: a systematic review and meta-analysis. Clin. Chim. Acta. 444, 260–263 (2015)

    Article  CAS  PubMed  Google Scholar 

  47. S.A. Polyzos, J. Kountouras, C.S. Mantzoros, Adipose tissue, obesity and nonalcoholic fatty liver disease. Minerva Endocrinol. (2016) [epub ahead of print]

  48. G. Thomas, A.R. Sehgal, S.R. Kashyap, T.R. Srinivas, J.P. Kirwan, S.D. Navaneethan, Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 6, 2364–2373 (2011)

    Article  PubMed  PubMed Central  Google Scholar 

  49. K.A. Toulis, A.D. Anastasilakis, S.A. Polyzos, P. Makras, Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. Hormones 10, 174–195 (2011)

    Article  PubMed  Google Scholar 

  50. E.G. Abate, B.L. Clarke, Review of Hypoparathyroidism. Front. Endocrinol. 7, 172 (2016)

    Google Scholar 

  51. J.P. Foo, S.A. Polyzos, A.D. Anastasilakis, S. Chou, C.S. Mantzoros, The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrhea. J. Clin. Endocrinol. Metab. 99, E2252–E2258 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. J.D. Christensen, A.O. Lungu, E. Cochran, M.T. Collins, R.I. Gafni, J.C. Reynolds, K.I. Rother, P. Gorden, R.J. Brown, Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J. Clin. Endocrinol. Metab. 99, E1493–E1500 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. T. Harslof, T. Sikjaer, L. Sorensen, S.B. Pedersen, L. Mosekilde, B.L. Langdahl, L. Rejnmark, The effect of treatment with pth on undercarboxylated osteocalcin and energy metabolism in hypoparathyroidism. J. Clin. Endocrinol. Metab. 100, 2758–2762 (2015)

    Article  PubMed  Google Scholar 

  54. A.L. Schafer, D.E. Sellmeyer, A.V. Schwartz, C.J. Rosen, E. Vittinghoff, L. Palermo, J.P. Bilezikian, D.M. Shoback, D.M. Black, Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J. Clin. Endocrinol. Metab. 96, E1982–E1989 (2011)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. E. Passeri, E. Dozio, M. Mendola, E. Costa, F. Bandera, M.M. Corsi Romanelli, S. Corbetta, Treatment with teriparatide might be associated with cardiometabolic changes in postmenopausal severe osteoporotic women. J. Biol. Regul. Homeost. Agents 29, 931–940 (2015)

    CAS  PubMed  Google Scholar 

  56. M. Maetani, G. Maskarinec, A.A. Franke, R.V. Cooney, Association of leptin, 25-hydroxyvitamin D, and parathyroid hormone in women. Nutr. Cancer 61, 225–231 (2009)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

    Stergios A. Polyzos

  2. Endocrine Unit, Evgenidion Hospital, University of Athens, Athens, Greece

    Leonidas Duntas

  3. Section of Specialized Endocrinology, Medical Clinic B, Oslo University Hospital, Oslo, Norway

    Jens Bollerslev

  4. Faculty of Medicine, University in Oslo, Oslo, Norway

    Jens Bollerslev

Authors
  1. Stergios A. Polyzos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leonidas Duntas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jens Bollerslev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stergios A. Polyzos.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Polyzos, S.A., Duntas, L. & Bollerslev, J. The intriguing connections of leptin to hyperparathyroidism. Endocrine 57, 376–387 (2017). https://doi.org/10.1007/s12020-017-1374-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-017-1374-6

Keywords

Search

Navigation